Rakovina Therapeutics Announces Extensions and Expansions of Strategic Collaborations to Support AI Research - Seite 2
“Over the next 12 to 16 weeks, we intend to screen six to eight billion compounds against our initial DDR target and anticipate synthesizing a short-list of the most promising novel drug candidates for in vitro and in vivo validation through our in-house laboratory infrastructure,” he added. Dr. Daugaard is also a professor at UBC.
“Our goal is to advance promising lead candidates toward clinical trials through collaboration with pharmaceutical development partners. With recent announcements of pre-clinical licensing deals in the DNA-damage response arena, we're confident in our ability to generate shareholder value in the near term,” said Bacha.
About Rakovina Therapeutics Inc.
Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response technologies. The Company has established a pipeline of novel DNA-damage
response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the United
States Food and Drug Administration and similar international regulatory agencies. Further information may be found at www.rakovinatherapeutics.com.
About Pharma Inventor Inc.
Pharma Inventor Inc. is a Canadian chemistry research and development and analytical services company located in Vancouver, British Colombia. Pharma Inventor was established in 2013 to provide
inventive and high-quality medicinal chemistry solutions in drug discovery research. Pharma Inventor has established a state-of-the-art medicinal chemistry facility relevant to AI-based drug
discovery. Its skilled team of international scientists serve the needs of pharmaceutical, biotech, research institutes and academic research groups to expedite their discovery R&D projects
with innovative chemistry solutions. Further information may be found at www.pharmainventor.com.
Lesen Sie auch
About the Vancouver Prostate Center at the University of British Columbia
The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence
and a designated Centre of Excellence for Commercialization and Research. The VPC hosted by the Vancouver Coastal Health Research Institute and the University of British Columbia.
Its research capabilities range from molecular biology to functional genomics and human clinical trials.